
Disruptive changes in mood and low energy level are among the most common reasons women consult a physician. Usually no clear physiological explantation for these changes can be found. Many physicians feel uncomfortable dealing with patients with these complaints. The purpose of this paper is to discuss a practical approach to helping women with such conditions. A variety of terms have been utilized to refer to the situation in which a female patient has decreased energy or labile mood. Premenstrual Syndrome (PMS) and chronic fatigue syndrome (CFS) are currently popular terms. An association of low mood with menstrual cycle phase is undoubted, with the late luteal-early premenstrual phase most commonly associated with depression and irritability. It seems likely that women with PMS and those without it do not differ in circulating hormone levels during their cycles but rather in the brain response to these. Estrogen and progesterone receptors exist in the brain and change during the cycle. Elaborate diagnostic efforts are rarely rewarding in managing mood and energy disorders. Of more value is a careful history particularly concerned with the pattern of mood changes and with life stresses, accompanied by a thorough physical examination and laboratory tests. In most cases, changes in mood and energy are a variant of clinical depression. Changes in energy and sleep may be more evident than low affect. Treatment with an appropriate antidepressant, usually a selective serotonin re-uptake inhibitor (SSRI), benefits most of these patients. Allowing the patient to express concerns about stressful life situations is often of great value.
Objective-Comparison of the effects of treatment of two transdermal therapeutic systems for estrogen replacement therapy with regard to efficacy, tolerability, and acceptance. Design-Open randomized. Setting-Multicenter. Patients and Interventions-A study population of 104 postmenopausal women was randomized on a 1:1 basis to treatment with one of two estradiol patches, Systen(R) (Cilag) and Estraderm(R) (Ciba-Geigy). Outcome Measures-Systolic and diastolic BP, hot flushes, night sweating, fatigue, insomnia, depression, nervousness, headache, vaginal discomfort (efficacy variables); bleeding, dermatological symptoms, comfort and adhesiveness of patch, and other possible causes of discontinuation (tolerability); general evaluation by patient (acceptance). Results-Considering all efficacy variables, 53% of Systen and 46% of Estraderm patients found the therapy satisfactory. Tolerability was somewhat higher in the Systen group. Adhesiveness of the patch was significantly better for Systen. Overall, 79% of Systen patients and 62% of Estraderm patients evaluated treatment as ''good'' or ''very good.'' The majority of patients in both groups found the patch very comfortable or only slightly obtrusive.
OBJECTIVE To examine the effect of oophorectomy on response to gonadotropin releasing hormone-agonist/human menopausal gonadotropin (GnRH-a/hMG) for in vitro fertilization (IVF). DESIGN Retrospective review. SETTING Tertiary care academic institution. PATIENTS Ninety-one infertile patients undergoing IVF. Eighty-four women had two ovaries and seven had only one ovary. RESULTS There was no difference observed between women with one versus two ovaries with regard to response to medications, hormone production, number of oocytes retrieved and fertilized, or the number of embryos cleaved and transferred. CONCLUSION Women with only one ovary are at no reproductive disadvantage when undergoing ovulation induction for IVF.
The relationship between endometriosis and infertility is observed frequently. Patients with both conditions require a conservative approach to their management. Since hormonal therapy is one of those approaches, we sought to compare the efficacy of Danazol and Gestrinone in 80 infertile patients (48 and 32, respectively). Therapy lasted 6 months in both treatment groups, and all patients studied had laboratory tests performed and were clinically evaluated and classified through laparoscopy before and after therapy. The improvement of symptoms and favorable follow-up were similar with both treatments. The reestablishment of menstrual patterns and fertility were also nearly alike in both groups. However, Gestrinone was associated with fewer secondary effects and is easier to administer than Danazol. We conclude that Gestrinone is a useful medication in the management of the infertile patient with endometriosis.
Objective-The purpose of this study was to compare the frequency with which pituitary suppression by gonadotropin releasing hormone agonists (GnRHa) for IVF is achieved according to hormonal vs. ultrasound criteria. Methods-The criteria selected for comparison were a luteinizing hormone (LH) level of <5 mIU/mL, an estradiol of <100 pmol/L and the absence of follicular development >10 mm on ultrasound. Results-Pituitary suppression was achieved in 184/215 cases (85.6%) according to the LH level, in 103/215 cases (47.9%) according to the estradiol level, and in 95/117 cases (81.2%) when ultrasound criteria were satisfied. All three criteria were met in only 16/139 (11.5%) of cases after 3 weeks' pretreatment with the GnRHa. Conclusion-Neither estradiol nor LH levels were predictive of the sonographic evidence of pituitary suppression, nor did they correlate with IVF outcome.